Metastasis Research Network (U54 Clinical Trial Not Allowed)

The National Cancer Institute is soliciting applications for U54 Specialized Research Centers to serve as the hub of the Metastasis Research Network (MetNet) under solicitation RFA-CA-27-012. The program aims to develop a comprehensive, systems-level understanding of cancer metastasis as a whole-body problem through interdisciplinary basic research. Each center must propose an overarching scientific theme pursued via two to three multidisciplinary projects focusing on the interplay between elements such as early dissemination, microenvironment crosstalk, dormancy, and therapeutic resistance. The initiative seeks the development of mechanistic models, clinically relevant experimental or in silico models, and tools for tracking metastatic cells in vivo. These cooperative agreements have a maximum project period of five years, with annual direct cost limits of 1.3 million dollars. A minimum of 50,000 dollars in direct costs must be allocated annually for post-award pilot projects from year two through five. Awardees are subject to governance by the MetNet Steering Committee, must undergo external evaluation, and are required to notify HHS of cybersecurity incidents within 48 hours of discovery. Funding decisions are based on scientific merit, program relevance, and fund availability, with a specific focus on the synergy and integration of the center's components. Applicants must maintain active SAM and eRA Commons registrations to be eligible.